Clinical trials: Cetuximab, open to volunteers
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
This study is a single center, randomized controlled, prospective phase II clinical trial to evaluate the efficacy and safety of cetuximab combined with dalpicilib compared to cetuximab monotherapy in patients with HPV-negative…
- Trial name
- NCT06935188
- Testing
- Dalpicilib combined with cetuximab, cetuximab
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
This is a multicenter, single-arm, phase II clinical study evaluating the efficacy and safety of neoadjuvant finotonlimab (anti-PD-1), cetuximab (anti-EGFR), and docetaxel in patients with resectable recurrent head and neck…
- Trial name
- BRIDGE (NCT07618624)
- Testing
- Finotonlimab, Cetuximab, Docetaxel
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer (CRC), Capecitabine
First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study
This multicenter, randomized, controlled, phase III study is conducted to evaluate the efficacy and safety of first line mCapOX plus Cetuximab versus mFOLFOX6 plus Cetuximab for RAS/BRAF wild-type, MSS, Unresectable Left-Sided…
- Conditions
- Colorectal Cancer (CRC), Capecitabine, Cetuximab
- Trial name
- CAPCET-III (NCT06616259)
- Testing
- mCapOX plus Cetuximab, mFOLFOX6 plus Cetuximab
- Where
- China
- Volunteers
- 452 people
- Sponsor
- Meng Qiu
Colorectal Neoplasms
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy…
- Trial name
- OrigAMI-3 (NCT06750094)
- Testing
- Amivantamab, Cetuximab, Bevacizumab
- Where
- 251 sites in United States, Australia and 24 more
- Volunteers
- 700 people
- Sponsor
- Janssen Research & Development, LLC
Betel-nut-associated Oral Carcinoma
Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell Carcinoma
The goal of this clinical trial is to learn the overall response rate of giving immunothrapy before surgery in treatment-naive, advanced stage patients with Betal-nut-associated oral cavity cancer.
- Trial name
- NCT07733466
- Testing
- Pembrolizumab and cetuximab
- Where
- Northern Mariana Islands
- Volunteers
- 20 people
- Sponsor
- Peter Brett, MD
Colorectal Neoplasms, RAS
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Colorectal cancer is a malignant tumor ranking among the top four in incidence and the top three in causes of death globally . Chemotherapy combined with anti-EGFR or anti-VEGF monoclonal antibodies is currently the standard…
- Conditions
- Colorectal Neoplasms, RAS, BRAF, Cetuximabβ
- Trial name
- concept (NCT07257653)
- Testing
- Cetuximab β；Fruquintinib；, Cetuximab β；Fruquintinib；anti-PD1 antibody；, Cetuximab β；Fruquintinib；anti-PD1/CTLA4 antibody
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Zhejiang University
LA HNSCC
Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
This prospective, single-arm, Phase II study aims to evaluate the efficacy, safety, and surgical conversion rate of Cetuximab combined with Tislelizumab and chemotherapy for unresectable LA HNSCC.
- Trial name
- NCT06978829
- Testing
- TP + Cetuximab + Tislelizumab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-Small Cell Lung Cancer, NSCLC
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
- Trial name
- NCT06917079
- Testing
- BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin)
- Where
- 17 sites in United States, Australia
- Volunteers
- 665 people
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Colorectal Cancer
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced…
- Trial name
- NCT07474727
- Testing
- AMT-676, 5-FU, Leucovorin
- Where
- 19 sites in China
- Volunteers
- 180 people
- Sponsor
- Multitude Therapeutics Inc.
Colorectal Cancer Metastatic
Real-World Study: Panitumumab N01 vs Cetuximab Plus FOLFOX in First-Line RAS Wild-Type mCRC
This is a prospective, observational, multicenter cohort study. Subjects will be divided into the Panitumumab N01 group (experimental group) and the cetuximab or cetuximab N01 group (control group) according to the treatment they…
- Trial name
- NCT07917429
- Testing
- Panitumumab N01, Cetuximab (EGFR inhibitor)
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Fujian Medical University Union Hospital
Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy
Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC
This is a two-arm, randomized phase II clinical study. It is planned to enroll 44 patients with primary left-sided, RAS and BRAF wild-type metastatic colorectal cancer.
- Trial name
- NCT07070713
- Testing
- FOLFOXIRI + QL1706 + Bevacizumab, FOLFOX+QL1706+Cetuximab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fujian Cancer Hospital
BRAF V600E, Colorectal Cancer
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the second leading cause of cancer-related death globally. BRAF V600E mutations occur in approximately 12% of metastatic CRC (mCRC) patients, conferring an extremely poor prognosis with a median overall…
- Conditions
- BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable)
- Trial name
- NCT07506109
- Testing
- Ipilimumab N01, Sintilimab, Cetuximab
- Where
- 4 sites in China
- Volunteers
- 49 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Colorectal Carcinoma
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
The presence of a BRAFV600E mutation is a marker of poor prognosis in patients with mCRC and associated with a median overall survival (mOS) of approximately 12 to 14 months compared to 20 to 25 months for patients with BRAF…
- Trial name
- BERING-CRC (NCT04673955)
- Testing
- Encorafenib, Cetuximab
- Where
- 70 sites in Austria, Germany
- Volunteers
- 500 people
- Sponsor
- Pierre Fabre Pharma GmbH
Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline
EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer
This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.
- Conditions
- Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline, Pancreatic Cancer Resectable
- Trial name
- NCT07698613
- Testing
- ASP-1929 photoimmunotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brown University
Advanced Solid Tumors
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 Monotherapy and in Combination with Other Agents in adult participants with advanced solid tumors
- Trial name
- NCT06973564
- Testing
- JAB-23E73, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 344 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Colorectal Cancer Metastatic to Liver
The QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colorectal Cancer Patients With Liver Metastases
The goal of this clinical trial is to learn if QL1706 (Iparomlimab/ Tuvonralimab)+ chemotherapy+ cetuximab/bevacizumab works to treat potentially resectable colorectal cancer patients with liver metastases in adults.
- Trial name
- NCT07863869
- Testing
- Arm A, Arm B
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer
Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer
As a result of the little benefit obtained from standard treatments and the poor prognosis of these patients, the BRAF-V600E mutant MSS aCRC represents an unmet medical need requiring clinical research.
- Trial name
- CEBBRA (NCT06207656)
- Testing
- EBC
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
This phase III trial compares cetuximab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer that may have spread from where it first…
- Conditions
- Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT07441681
- Testing
- Biospecimen Collection, Carboplatin, Cetuximab
- Where
- 150 sites in United States
- Volunteers
- 454 people
- Sponsor
- NRG Oncology
Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorectal cancer that has not responded to previous treatment (refractory)…
- Conditions
- Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT06102902
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection
- Where
- 16 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer.
- Trial name
- MOUNTAINEER-03 (NCT05253651)
- Testing
- tucatinib, trastuzumab, bevacizumab
- Where
- 366 sites in United States, Argentina and 23 more
- Volunteers
- 400 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer